Biotech company Immutep (ASX:IMM), specialises in immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent by the European Patent Office.
The patent is entitled “Combined Preparations for the Treatment of Cancer”
It protects Immutep’s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate efti-lagimod alpha (“efti” or “IMP321”) and a chemotherapy agent.
The patent expiry date is 19 December 2034.
Shares in Immutep (ASX:IMM)